Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: From preclinical testing to first-in-human study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Acta Pharmaceutica Sinica B

Topics

Medicine

Cancer Oncology

Epidemiology

Internal Medicine

Neurology

Show all topics

DOI

10.1016/j.apsb.2024.05.022

License

CC-BY-NC-ND